Literature DB >> 7133598

Estradiol receptor in human breast cancers throughout the menstrual cycle.

E Heise, M Görlich.   

Abstract

The existence and the concentration of the estradiol receptor (ER) in breast cancers of pre- and postmenopausal patients were measured. ER status and concentration are significantly higher in cancers of postmenopausal women. Breast cancers operated at various phases of the menstrual cycle showed remarkable differences in ER incidence and concentration. The highest values were found in the early proliferative phase, whereas the ER incidence is lowest in cancers which were operated at early secretory phase. ER concentrations found in late proliferative and late secretory phases are significantly lower than those found in cancers of postmenopausal patients. Statistically significant differences of the ER concentrations between the various phases of the menstrual cycle could not be secured.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7133598     DOI: 10.1159/000225667

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  4 in total

1.  Changes in estrogen and progesterone receptor content of primary breast carcinoma during the menstrual cycle.

Authors:  D A Weimer; W L Donegan
Journal:  Breast Cancer Res Treat       Date:  1987-12       Impact factor: 4.872

Review 2.  William L. McGuire Memorial Symposium. Estrogen and progestin effects in human breast carcinogenesis.

Authors:  R J King
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

3.  Influence of the menstrual cycle on the concentrations of estrogen and progesterone receptors in primary breast cancer biopsies.

Authors:  C M Smyth; D E Benn; T S Reeve
Journal:  Breast Cancer Res Treat       Date:  1988-04       Impact factor: 4.872

4.  Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy.

Authors:  K Holli; J Isola; M Hakama
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.